title: High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: a phase II study.
abstract: Sixteen patients with metastatic nonseminomatous testicular cancer refractory to cisplatinum combination chemotherapy, were treated with epirubicin 100-120 mg/m2 q d 22. One partial remission lasting 6 months was achieved. Two additional patients had stabilisation of disease for 3 and 4 months. Median time to progression was 43 days. Myelosuppression was dose-limiting, with a WBC nadir of 1900/microliters. 4/30 cycles (13%) were associated with granulocytopenic fever. One patient developed a decline in cardiac ejection fraction without clinical signs of congestive heart failure. Epirubicin in this dosage and schedule has no major therapeutic activity in heavily pretreated non-seminomatous testicular cancer.
authors: Department of Hematology/Oncology, University of Hannover Medical School, FRG.
authors: A
authors: A
authors: Harstrick
authors: H J
authors: HJ
authors: Schmoll
authors: H
authors: H
authors: Wilke
authors: C
authors: C
authors: Schöber
authors: M
authors: M
authors: Stahl
authors: C K
authors: CK
authors: Wömpner
authors: C
authors: C
authors: Bokemeyer
authors: G
authors: G
authors: Dölken
authors: K
authors: K
authors: Burk
authors: H
authors: H
authors: Poliwoda
mesh_terms: D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012074:Remission Induction; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D015251:Epirubicin